How are you taking part in this consultation?

You will not be able to change how you comment later.

You must be signed in to answer questions

  • Question on Consultation

    Has all of the relevant evidence been taken into account?

  • Question on Consultation

    Are the summaries of clinical and cost effectiveness reasonable interpretations of the evidence?

  • Question on Consultation

    Are the recommendations sound and a suitable basis for guidance to the NHS?

  • Question on Consultation

    Are there any aspects of the recommendations that need particular consideration to ensure we avoid unlawful discrimination against any group of people on the grounds of age, disability, gender reassignment, pregnancy and maternity, race, religion or belief, sex or sexual orientation?

Acalabrutinib and venetoclax with or without obinutuzumab for untreated chronic lymphocytic leukaemia

Open for comments Open until   Request commenting lead permission

We have updated this service so that members of the same organisation can now collaborate on a joint online response.

Read our blog to learn more.

2 Information about acalabrutinib and venetoclax

Marketing authorisation indication

2.1

Acalabrutinib (Calquence, AstraZeneca) in combination with venetoclax (Venclyxto, AstraZeneca) with or without obinutuzumab is indicated for 'the treatment of adult patients with previously untreated chronic lymphocytic leukaemia (CLL)'.

Dosage in the marketing authorisation

Price

2.3

The list price for acalabrutinib is £5,059.00 for a 60 tablet pack of 100-mg tablets. The list price of venetoclax varies depending on the pack size and dose (excluding VAT; company submission).

2.4

The company has a commercial arrangement, which would have applied if acalabrutinib and venetoclax had been recommended.

Sustainability

2.5

Information on the Carbon Reduction Plan for UK carbon emissions for AstraZeneca will be included here when guidance is published.